NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
NervGen Pharma said independent, blinded biomechanical gait analyses in its Phase 1b/2a CONNECT SCI study found NVG-291 produced “genuine neural recovery” signals versus placebo. The Global Statistical Test showed a significant global treatment effect (GTE +0.45; p=0.0197) and 100% (10/10) responders vs 10% (1/10) placebo (p=0.0001), with consistent improvements across coordination, mechanical effort and postural stability.
How this was made
The 30-second read
Why it matters
Independent, blinded biomechanical gait analyses add objective, multi-domain evidence consistent with genuine neural recovery, potentially increasing probability of success and improving the narrative for RESTORE initiation in mid-2026.
Market read
A statistically significant, independently verified biomechanical efficacy signal can drive a valuation re-rate for NGEN and increase speculative/positioning activity ahead of Phase 3 milestones.
What to watch
The article emphasizes biomechanical hallmarks but does not provide safety/tolerability details here; traders may wait for full clinical context and endpoint durability.
Background
NVG-291 is a subcutaneously administered neuroreparative peptide targeting the inhibitory CSPG-PTPσ pathway for chronic tetraplegia; CONNECT SCI is Phase 1b/2a and RESTORE is the planned Phase 3 registrational study.
Ticker impact
NervGen reported independent, blinded biomechanical gait analyses showing statistically significant “genuine neural recovery” with NVG-291 in Phase 1b/2a CONNECT SCI.
Likely near-term positive bias for NGEN on biotech momentum, with follow-through tied to Phase 3 execution and FDA interactions.
The release cites multiple statistically significant endpoints (GST p=0.0197; responder p=0.0001) plus independent blinded verification, which typically drives re-rating in clinical-stage neuro/SCI names.
Market effects
Reinforces investor appetite for neuroreparative SCI therapeutics using objective digital/biomechanical endpoints to de-risk mechanism-of-action claims.
Primarily US biotech sentiment; potential spillover to other small-cap clinical-stage neuro/SCI developers trading on read-across efficacy credibility.
Independent academic verification and FDA-aligned Phase 3 planning can improve global investor confidence in trial design and endpoints.
Counterpoint
Responder classification is based on a small sample (10/10 vs 1/10), so results could be sensitive to variability and may not fully translate to Phase 3.
Key entities
- companyNervGen Pharma Corp.
Clinical-stage biopharmaceutical developing NVG-291 for spinal cord injury; announced positive independent blinded gait analyses.
- productNVG-291
Neuroreparative peptide candidate evaluated in CONNECT SCI for chronic tetraplegia.
- service_providerNewton Tech
AI-powered movement intelligence company that conducted the video-based biomechanical gait analyses.
- regulatorFDA
Referenced for prior End-of-Phase 2 meeting and alignment on the Phase 3 RESTORE study.
